We are proud to announce that MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its innovative regenerative cell therapy for Exstrophy-Epispadias-Complex.
Charité – Universitätsmedizin Berlin and the Samsung Comprehensive Cancer Center in Seoul have signed a memorandum of understanding. As part of this partnership, the Charité Comprehensive Cancer Center (CCCC) and the Samsung Comprehensive Cancer…
The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will…
DEEP – Institute for Deep Tech Innovation at ESMT Berlin has signed a three-year partnership agreement with Bayer to jointly strengthen the translation of cutting-edge technologies in life sciences as well as biotech and healthtech startups.
Researchers from the Leibniz Institute on Aging in Jena and the Brandenburg University of Technology Cottbus-Senftenberg have discovered a novel treatment approach for soft tissue tumors, which are frequently occurring in children and are often…
Climate change and health, digital technologies for global health, pandemic prevention, the global health priorities of the G7/G20 nations, and the 75th anniversary of WHO are the focus of this year's World Health Summit in Berlin. From October…
Prof. Surjo Soekadar, Einstein Professor of Clinical Neurotechnology at Charité – Universitätsmedizin Berlin, works in the field of advanced technologies for brain stimulation and brain-computer interfaces. He and his team develop and test systems…
At Bayer, we’re passionate about enabling and supporting great ideas in healthcare – We are proud to sponsor Bio Europe’s Startup Spotlight (November 6–8, 2023 in Munich, Germany).
The Arl8b protein provides new insights into the mechanisms underlying Alzheimer’s disease. It also has the potential to function as a diagnostic marker. The scientists behind this discovery, a team led by Erich Wanker from the Max Delbrück Center,…
A New Clinical Study in Europe Examines the Applicability and Effectiveness of the New TIMELY Platform for Telemedical Secondary Prevention
